Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in moderate to severe chronic plaque psoriasis (I1F-MC-RHAZ)
2011-002970-22Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of ixekizumab in plaque psoriasis, sponsored by Eli Lilly and Company. Primary endpoints: Static Physician Global Assessment (sPGA) at 12 weeks and Psoriasis Area and Severity Index (PASI) at 12 weeks. Started Dec 2011; status: completed.
02
Drugs
ixekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2011-002970-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002970-22.